l-Deprenyl in atypical depressives.
Arch Gen Psychiatry
; 41(8): 777-81, 1984 Aug.
Article
in En
| MEDLINE
| ID: mdl-6430257
ABSTRACT
We investigated the antidepressant efficacy of l-deprenyl (selegiline), a selective monoamine oxidase B inhibitor (MAOI), in a six-week open trial of 17 patients with atypical depression. Such patients have previously been shown to benefit from nonselective MAOIs such as phenelzine sulfate. Ten patients (59%) responded to l-deprenyl, but nine required dosages above the 10 to 20 mg/day used in previous investigations. l-Deprenyl was superior to six weeks of placebo administered to diagnostically similar patients in a separate double-blind study. In contrast with previous findings with pheneizine, responders to l-deprenyl differed from nonresponders by having lower baseline anxiety ratings. Even at high dosages, there appeared to be fewer side effects with l-deprenyl than with nonselective MAOIs.
Search on Google
Database:
MEDLINE
Main subject:
Phenethylamines
/
Selegiline
/
Depressive Disorder
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Year:
1984
Type:
Article